CN112358494A - 一种基于吖啶的碳硼烷衍生物及其在生物显影中的应用 - Google Patents
一种基于吖啶的碳硼烷衍生物及其在生物显影中的应用 Download PDFInfo
- Publication number
- CN112358494A CN112358494A CN202010273835.XA CN202010273835A CN112358494A CN 112358494 A CN112358494 A CN 112358494A CN 202010273835 A CN202010273835 A CN 202010273835A CN 112358494 A CN112358494 A CN 112358494A
- Authority
- CN
- China
- Prior art keywords
- carborane
- acridine
- alkyl
- hydroxyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 238000011161 development Methods 0.000 title abstract description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 10
- 229910052796 boron Inorganic materials 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 238000012984 biological imaging Methods 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 238000004020 luminiscence type Methods 0.000 claims 1
- 238000006862 quantum yield reaction Methods 0.000 abstract description 8
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000002776 aggregation Effects 0.000 abstract description 3
- 238000004220 aggregation Methods 0.000 abstract description 3
- 238000013461 design Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000004607 11B NMR spectroscopy Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- CKTUEZIFXPDRMO-UHFFFAOYSA-N 9,9-dimethyl-10-phenylacridine Chemical compound C12=CC=CC=C2C(C)(C)C2=CC=CC=C2N1C1=CC=CC=C1 CKTUEZIFXPDRMO-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- YKFRPCRADQOKOA-UHFFFAOYSA-N 10-(4-bromophenyl)-9,9-dimethylacridine Chemical compound C12=CC=CC=C2C(C)(C)C2=CC=CC=C2N1C1=CC=C(Br)C=C1 YKFRPCRADQOKOA-UHFFFAOYSA-N 0.000 description 1
- PVZTYVPUWQVNQT-UHFFFAOYSA-N 10-(4-ethynylphenyl)-9,9-dimethylacridine Chemical compound CC1(C)C2=CC=CC=C2N(C(C=C2)=CC=C2C#C)C2=C1C=CC=C2 PVZTYVPUWQVNQT-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- VHJLUZTYLJKNHE-UHFFFAOYSA-N 9,9-dimethyl-10-[4-(2-phenylethynyl)phenyl]acridine Chemical compound CC1(C2=CC=CC=C2N(C=2C=CC=CC1=2)C1=CC=C(C=C1)C#CC1=CC=CC=C1)C VHJLUZTYLJKNHE-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
- A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0026—Acridine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1096—Heterocyclic compounds characterised by ligands containing other heteroatoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明属于有机发光材料领域,具体涉及一种基于吖啶的碳硼烷衍生物及其作为硼中子捕获试剂在生物显影中的应用。
背景技术
诊疗一体化是当前癌症治疗的发展趋势,硼中子捕获疗法是一种无需开刀化疗便可治疗癌症的一种方法,利用10B的同位素在外加中子源照射的情况下即可产生γ射线,且其辐射长度仅为一个细胞的范围,因此发展可用于硼中子捕获疗法的生物显影剂也尤为重要。由于生物体系荧光背景多,体系复杂,因此大多数生物显影分子均为红光、近红外光为主。碳硼烷因分子结构种含有十个硼原子,是一种潜在的硼中子捕获试剂。近年来,有不少利用碳硼烷调控有机分子发光的研究,但设计最大发光波长在650nm以上的高效红光分子却很少。L.Weber等人报道了一种碳硼烷红光材料,其结构为:C-diazaborolyl-ortho-carboranes,1-R’-2-H-1,2-C2B10H10,R’=2-(1,3-iPr2-1,3,2-N2BC6H4)-。但是将该碳硼烷红光材料调控至654nm,此发光波长下的量子产率仅有5%,不能满足实际生物显影的要求(L.Weber,J.Kahlert,L.A.Brockhinke,H.-G.Stammler,B.Neumann,R.A.Harder,P.J.Low,M.A.Fox,Dalton Trans.2013,42,2266-2281.)。最大发射波长在650nm以上的分子,量子产率甚至在仪器检测之下。(a)S.-Y.Kim,Y.-J.Cho,G.F.Jin,W.-S.Han,H.-J.Son,D.W.Cho,S.O.Kang,Phys.Chem.Chem.Phys.2015,17,15679-15682;b)K.Nishino,K.Tanaka,Y.Chujo,Asian J.Org.Chem.2019,8,2228-2232.)。T.Chen等公开了利用9,9-二甲基-10-苯基-9,10-二氢吖啶分子为电子供体构建的有机橙红光分子的研究,但该分子结构复杂,共轭链长,合成繁复等缺点而阻碍了其在生命体系中的应用(T.Chen,C.-H.Lu,C.-W.Huang,X.Zeng,J.Gao,Z.Chen,Y.Xiang,W.Zeng,Z.Huang,S.Gong,C.-C.Wu,C.Yang,J.Mater.Chem.C 2019,7,9087-9094)。因此,设计发光高效、合成简便的碳硼烷和吖啶分别为电子受体与供体的红光分子,具有重要的实际应用意义。
发明内容
本发明针对现有技术不足,提供了一种基于吖啶的碳硼烷衍生物,该化合物最大发射波长在650nm以上,量子产率高,具有合成步骤简便、发光性质优异、显色效果好的优点。
本发明具体技术方案如下:
一种基于吖啶的碳硼烷衍生物具有如下结构:
其中,R1和R2相同或者不同,代表H,C1-C8的烷基或一个或多个位置被H,C1-C8的烷基、羟基、氨基、卤素基团中的一种或几种取代的苯基;R3~R19相同或者不同,代表H,C1-C8的烷基、羟基、氨基或卤素基团。
优选的,R1和R2相同或者不同,代表H,C1-C6的烷基(优选甲基、乙基、丙基、异丙基)或一个或多个位置被H,C1-C6的烷基(优选甲基、乙基、丙基、异丙基)、羟基、氨基、F、Cl、Br、I中的一种或几种取代的苯基;R3~R19相同或者不同,代表H,C1-C6的烷基(优选甲基、乙基、丙基、异丙基)、羟基、氨基、F、Cl、Br或I。
优选的本发明所述的基于吖啶的碳硼烷衍生物,具有如下结构:
本发明所述化合物可以采用炔烃插入硼笼分子合成碳硼烷的方法制备。
上述制备方法所用的溶剂甲苯为干燥试剂,反应在无水无氧及回流条件下反应72小时,冷却至室温后,甲醇淬灭即可。然后减压蒸馏浓缩,用柱层析分离提纯,真空干燥。
本发明另一目的在于提供本发明所述的基于吖啶的碳硼烷衍生物在制备硼中子捕获试剂中的应用。
进一步的,所述的应用是指基于吖啶的碳硼烷衍生物在制备生物显影剂或抗肿瘤药物中的应用。
本发明所述化合物结构中的碳硼烷三维立体结构具有聚集诱导发光性质,并且生物毒性低,可被细胞内吞,能够实现细胞显影,可作为生物显影剂或者抗肿瘤药物用于硼中子捕获疗法。
本发明优点:
1.本发明基于硼中子捕获疗法的生物显影剂和诊疗一体化潜在药物的设计构思,利用碳硼烷对发色团的红移调控作用及碳硼烷本身的修饰,获得最大发射波长为675nm(发射光调节至CIE色坐标为(0.65,0.35)),固态量子产率达35%的高效深红光分子。本发明所述的碳硼烷衍生物实现了高效的深红光发射,为目前碳硼烷在此发射波长下固态量子产率最高的有机小分子。
2.本发明设计的碳硼烷衍生物具有合成容易且高效,操作简便。
3.本发明所述的碳硼烷分子具有聚集诱导发光及生物相容性的特点,成功用于生物显影,为后续设计诊疗一体化潜在药物奠定基础。
附图说明
图1为本发明所述碳硼烷衍生物的晶体结构。
图2为本发明所述碳硼烷衍生物的固态发射光谱。
图3为本发明所述碳硼烷衍生的CIE(Commission Internationale de L’Eclairage)坐标。
图4为本发明所述碳硼烷衍生物的细胞显影图。从左到右依次是明场下、暗场下和混合模式下的细胞显影图。
具体实施方式
以下通过实施例说明本发明的具体步骤,但不受实施例限制。
在本发明中所使用的术语,除非另有说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实例并参照数据进一步详细描述本发明。应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
在以下实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
实施例1
化合物1
步骤一:9,9-二甲基-10-(4-苯乙炔基苯基)-9,10-二氢吖啶的制备:氩气保护条件下,将1.0equiv.9,9-二甲基-10-(4-溴苯基)-9,10-二氢吖啶、1.1equiv.苯炔、5%molequiv.Pd(PPh3)4、10%mol equiv.CuI,无水THF:Et3N=1:1,回流反应12h。终止反应冷却室室温,将溶剂旋转蒸发至干燥,硅胶柱层析纯化,二氯甲烷与石油醚为洗脱剂,真空干燥得到白色粉末。
步骤二:化合物1的制备:氩气氛围下,向反应瓶中加入1.0equiv.9,9-二甲基-10-(4-乙炔基苯基)-9,10-二氢吖啶和1.2-1.5equiv.B10H12(CH3CN)2,在干燥甲苯溶剂下回流36-72h,至原料点消失。冷却至室温后,加入适量甲醇,室温搅拌1h后减压蒸馏除去溶剂,剩余物用硅胶柱层析纯化,二氯甲烷与石油醚为洗脱剂,真空干燥得到白色粉末。1H NMR(400MHz,CDCl3)δ7.66(d,J=8.5Hz,2H),7.48(d,J=7.5Hz,2H),7.42(d,J=6.5Hz,2H),7.33(m,1H),7.21(t,J=7.6Hz,2H),7.09(d,J=8.4Hz,2H),6.90(m,4H),5.82(d,J=8.5Hz,2H),3.11–2.13(br,10H,B-H),1.63(s,6H).11B NMR(128MHz,CDCl3)δ-2.2(4B),-10.3(6B).13C NMR(101MHz,CDCl3)δ143.3,140.4,133.5,131.2,130.9,130.7,130.6,130.3,128.4,126.4,125.5,121.1,113.9,85.4(Ccarborane),84.5(Ccarborane),36.1,31.3.HRMS:m/z calcd for C29H33B10N[M]+:505.3544.Found:505.3653IR(KBr):(νcm-1)2583(B-H)。
实施例2
化合物2
可参考实施例1所述方法将9,9-二甲基-10-(4-溴苯基)-9,10-二氢吖啶与三甲基硅乙炔反应,用碳酸钾脱硅保护基得到9,9-二甲基-10-(4-乙炔基苯基)-9,10-二氢吖啶,之后与B10H12(CH3CN)2反应,得到白色粉末。1H NMR(400MHz,CDCl3)δ7.74(m,2H),7.47(m,2H),7.32(m,2H),6.97(m,4H),6.18(m,2H),4.06(s,1H,Ccarborane-H),3.36-1.89(br,10H,B-H),1.67(s,6H).11B NMR(128MHz,CDCl3)δ-1.7(2B),-4.1(2B),-8.7(2B),-10.7(2B),-12.6(2B).13C NMR(101MHz,CDCl3)δ143.3,140.5,133.4,131.8,130.5,130.4,126.6,125.6,121.2,114.1,76.0(Ccarborane),60.6(Ccarborane-H),36.2,31.3.HRMS:m/z calcd forC23H29B10N[M]+:644.3631.Found:664.3689IR(KBr):(νcm-1)2578(B-H)。
实施例3
化合物3
反应路线如下:
B-3化合物的制备:通过2.0equiv.9,9-二甲基-10-(4-溴苯基)-9,10-二氢吖啶与2.0equiv.丁二炔酸,5%mol equiv.Pd(PPh3)2Cl2,10%molequiv.1,4-双(二苯基膦)丁烷(dppb)与2.0equiv.1,8-二氮杂二环十一碳-7-烯(DBU)的条件下,溶于冷冻除氧的DMSO溶液中,在110℃加热反应12h。反应完全后冷却至室温,加入饱和氯化铵水溶液,用乙醚萃取三次,卤水洗涤,无水硫酸镁干燥,过滤,浓缩,柱层析分离以67%的收率得到白色炔烃产物。
化合物3的制备:参考实施例1步骤二的方法制备得到化合3。1H NMR(400MHz,CDCl3)δ7.71(d,J=8.5Hz,4H),7.39(d,J=7.0Hz,4H),7.21(d,J=8.5Hz,4H),6.80(t,J=7.4Hz,4H),6.67(t,J=8.1Hz,4H),6.00(d,J=8.1Hz,4H),3.52–1.85(br,10H,B-H),1.62(s,12H).11B NMR(128MHz,CDCl3)δ-1.3(4B),-9.5(6B).13C NMR(101MHz,CDCl3)δ143.8,140.4,133.3,130.9,130.8,130.4,126.6,125.2,121.2,114.2,84.3(Ccarborane),36.1,30.8.HRMS:m/z calcd for C44H46B10N2[M]+:712.4592.Found:712.4608IR(KBr):(νcm-1)2589(B-H)。
实施例4
采用CCD-Bruker Smart APEX 11收集化合物1-3的衍射强度数据,使用Olex2程度解析结构并用Mercury软件绘制出球棍模型,化合物1和3的晶体结构如图1所示。
使用Hitachi F-4600荧光分光光度仪检测化合物1-3的荧光光谱,结果如图2所示。使用Horiba FL-3三维荧光光谱仪,积分球下测定化合物1-3的绝对量子产率和荧光寿命,结果如表1所示。
表1化合物1-3光物理性质表
化合物1 | 化合物2 | 化合物3 | |
λ<sub>em</sub>(nm) | 675 | 585 | 705 |
QY(%) | 31.3 | 1.8 | 1.1 |
τ(ns) | 78.9 | 17.7 | 19.9 |
通过CIE坐标软件计算化合物1-3发射光谱的色坐标,如图3所示,结果表明化合物1化合物处于深红光范围内,化合物2处于黄光范围内,化合物3处于橙红光范围内。表1对比结果表明,化合物1具有高量子产量和荧光寿命。
实施例5
将0.2mg化合物1溶于2mL DMSO中,在Hela细胞培养皿中分别加入1mL化合物1溶液,此时化合物在水相培养基条件下形成聚集态,并放置于37℃,5%CO2的培养箱中2h,之后用磷酸缓冲溶液洗涤两次,去除背景。使用德国徕卡生产的MALDI TOF-TOF 4800plus双光子激光共聚焦显微镜检测化合物1在Hela细胞中的显影图,如图4所示。结果表明化合物1可以进入细胞质中,且为亮点发光,说明化合物1的聚集态颗粒可进入细胞质中,实现癌症细胞的的成像。
Claims (7)
2.根据权利要求1所述的基于吖啶的碳硼烷衍生物,其特征在于R1和R2相同或者不同,代表H,C1-C6的烷基或一个或多个位置被H,C1-C6的烷基、羟基、氨基、F、Cl、Br、I中的一种或几种取代的苯基;R3~R19相同或者不同,代表H,C1-C6的烷基、羟基、氨基、F、Cl、Br或I。
3.根据权利要求2所述的基于吖啶的碳硼烷衍生物,其特征在于R1和R2相同或者不同,代表H,甲基、乙基、丙基、异丙基或一个或多个位置被H,甲基、乙基、丙基、异丙基、羟基、氨基、F、Cl、Br、I中的一种或几种取代的苯基;R3~R19相同或者不同,代表H,甲基、乙基、丙基、异丙基、羟基、氨基、F、Cl、Br或I。
5.根据权利要求1-4任一项所述的基于吖啶的碳硼烷衍生物在制备硼中子捕获试剂中的应用。
6.根据权利要求5所述的应用,其特征在于所述的基于吖啶的碳硼烷衍生物在制备生物显影剂或抗肿瘤药物中的应用。
7.根据权利要求5所述的应用,其特征在于所述的基于吖啶的碳硼烷衍生物最大发光波长在650nm以上。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010273835.XA CN112358494B (zh) | 2020-04-09 | 2020-04-09 | 一种基于吖啶的碳硼烷衍生物及其在生物显影中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010273835.XA CN112358494B (zh) | 2020-04-09 | 2020-04-09 | 一种基于吖啶的碳硼烷衍生物及其在生物显影中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112358494A true CN112358494A (zh) | 2021-02-12 |
CN112358494B CN112358494B (zh) | 2021-09-28 |
Family
ID=74516379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010273835.XA Active CN112358494B (zh) | 2020-04-09 | 2020-04-09 | 一种基于吖啶的碳硼烷衍生物及其在生物显影中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112358494B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000045857A2 (de) * | 1999-02-01 | 2000-08-10 | Schering Aktiengesellschaft | Metallmakrozyklen für zweischritt-strahlentherapieformen |
CN101268085A (zh) * | 2005-08-19 | 2008-09-17 | 海默尔凯普股份公司 | 用于硼中子俘获治疗的硼化合物 |
CN101605459A (zh) * | 2006-12-04 | 2009-12-16 | 布鲁克哈文科学协会有限责任公司 | 碳硼烷基卟啉及其应用 |
CN104151339A (zh) * | 2013-05-17 | 2014-11-19 | 中国科学院近代物理研究所 | 含硼吖啶衍生物、其制备方法和应用 |
CN104610328A (zh) * | 2015-02-03 | 2015-05-13 | 西安近代化学研究所 | 一种烷基碳硼烷衍生物的合成方法 |
CN106866716A (zh) * | 2017-04-28 | 2017-06-20 | 南京大学 | 一种碳硼烷衍生物及其制备方法及用途 |
CN109852378A (zh) * | 2019-01-23 | 2019-06-07 | 广东工业大学 | 一种热活化延迟荧光深红光材料及其电致发光器件 |
CN110526934A (zh) * | 2019-08-30 | 2019-12-03 | 武汉华星光电半导体显示技术有限公司 | 红光热活化延迟荧光材料及其合成方法、显示面板 |
-
2020
- 2020-04-09 CN CN202010273835.XA patent/CN112358494B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000045857A2 (de) * | 1999-02-01 | 2000-08-10 | Schering Aktiengesellschaft | Metallmakrozyklen für zweischritt-strahlentherapieformen |
CN101268085A (zh) * | 2005-08-19 | 2008-09-17 | 海默尔凯普股份公司 | 用于硼中子俘获治疗的硼化合物 |
CN101605459A (zh) * | 2006-12-04 | 2009-12-16 | 布鲁克哈文科学协会有限责任公司 | 碳硼烷基卟啉及其应用 |
CN104151339A (zh) * | 2013-05-17 | 2014-11-19 | 中国科学院近代物理研究所 | 含硼吖啶衍生物、其制备方法和应用 |
CN104610328A (zh) * | 2015-02-03 | 2015-05-13 | 西安近代化学研究所 | 一种烷基碳硼烷衍生物的合成方法 |
CN106866716A (zh) * | 2017-04-28 | 2017-06-20 | 南京大学 | 一种碳硼烷衍生物及其制备方法及用途 |
CN109852378A (zh) * | 2019-01-23 | 2019-06-07 | 广东工业大学 | 一种热活化延迟荧光深红光材料及其电致发光器件 |
CN110526934A (zh) * | 2019-08-30 | 2019-12-03 | 武汉华星光电半导体显示技术有限公司 | 红光热活化延迟荧光材料及其合成方法、显示面板 |
Non-Patent Citations (2)
Title |
---|
A. FILIPA F. DA SILVA. ET AL: ""Synthesis, characterization and biological evaluation of carboranylmethylbenzo[b]acridones as novel agents for boron neutron capture therapy"", 《ORG. BIOMOL. CHEM》 * |
陈文等: ""碳硼烷及其在核医学领域的应用研究进展"", 《同位素》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112358494B (zh) | 2021-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108440475B (zh) | 一种区分不同极性脂滴的比率型荧光探针及其制备方法和应用 | |
Li et al. | Using highly emissive and environmentally sensitive o-carborane-functionalized metallophosphors to monitor mitochondrial polarity | |
CN110218220A (zh) | 一种功能化金属-有机框架化合物、其形成的复合物及其制备方法和应用 | |
Zhang et al. | Near-infrared (NIR) emitting Nd/Yb (III) complexes sensitized by MLCT states of Ru (II)/Ir (III) metalloligands in the visible light region | |
CN105859778A (zh) | 一种具有余辉发光性能的超长寿命纯有机磷光材料及其制备方法与应用 | |
Hu et al. | “AIE+ ESIPT” bis Schiff-base ligands with multicolor emission and their corresponding Eu (III) complexes: Synthesis and properties research | |
CN112358494B (zh) | 一种基于吖啶的碳硼烷衍生物及其在生物显影中的应用 | |
CN107880076B (zh) | 一种磷光金属配合物的制备方法和应用 | |
CN114874145B (zh) | 一种水溶性三苯甲基类自由基材料及其制备方法和应用 | |
CN107759504A (zh) | 一种固液态均具较强荧光的双相有机荧光材料及制备方法 | |
CN108997384B (zh) | 一类螺环银簇发光簇合物及其制备方法与应用 | |
CN108017676B (zh) | 一种多羟基黄色磷光铱配合物及其制备方法 | |
Li et al. | A novel phosphorescent iridium (III) complex bearing a donor–acceptor-type o-carboranylated ligand for endocellular hypoxia imaging | |
CN113278036B (zh) | 一种含吩噻嗪铱配合物及其制备方法和应用 | |
CN112175607B (zh) | 有机室温磷光材料及其制备方法和应用 | |
CN112694500B (zh) | 一类新型膦氧双齿中性锰配合物及其制备方法与应用 | |
CN110105381B (zh) | 一类香豆素为骨架的β-二酮氟化硼荧光染料的制备和应用 | |
CN102887915A (zh) | 杂核双金属配合物发光材料及其制备方法和用途 | |
Sankar et al. | Design and Synthesis of new binuclear photo luminescent Europium (III) complex | |
Voloshin et al. | Spiropyrans and spirooxazines 10. Synthesis of photochromic 5′-(1, 3-benzoxazol-2-yl)-substituted spiro [indoline-naphthopyrans] | |
CN113308129B (zh) | 同质多晶的对称二四苯乙烯荧光化合物制备方法及其晶体 | |
CN104447874A (zh) | 金属配合物的制备及其应用方法 | |
KR101255255B1 (ko) | 로다민 유도체 및 이의 제조방법 | |
CN107129512A (zh) | 一种含硒原子的荧光探针及其制备方法与应用 | |
CN110283193B (zh) | 一种具有研磨固态发光性质的荧光探针化合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |